NIH· @NIH · X·· 8 天前AI 评分30
AI 导读
美国 FDA 批准 Oveporexton，这是首款针对发作性睡病 1 型的疗法，可恢复控制觉醒的神经化学过程并覆盖该病全部症状。NIH 表示，该新疗法的研发凸显了投资脑功能基础科学研究的重要性，其数十年来持续资助发作性睡病与失眠研究。
正文
DYK: NIH has funded decades of research on narcolepsy and insomnia. 😴
Recently, the U.S. FDA approved Oveporexton, the first narcolepsy type 1 treatment to restore the neurochemical process that controls alertness and address the condition's full range of symptoms.
The development of this novel treatment highlights the importance of investing in basic scientific research into how the brain functions.
🧐Want to know more about NIH's legacy with neuroscience research?
Check out our virtual timeline! ➡️ https://bit.ly/4dv6Ysl
来源：NIH · x.com